AN INHALABLE FORMULATION OF FLUTICASONE PROPIONATE AND ALBUTEROL SULFATE

This invention relates to a fixed-dose dry powder inhalation formulation comprising fluticasone propionate and albuterol sulfate, together with an α-lactose monohydrate carrier. In the formulation, the albuterol sulfate stabilises fluticasone propionate.

Saved in:
Bibliographic Details
Main Authors O'NEILL, Brian Paul, BLAIR, Julian Alexander, EDLIN, Chris David, SHAH, Hardik Kirtikumar, MCKEON, Shane Michael
Format Patent
LanguageEnglish
French
German
Published 21.06.2023
Subjects
DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY
DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROMTHE BODY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:This invention relates to a fixed-dose dry powder inhalation formulation comprising fluticasone propionate and albuterol sulfate, together with an α-lactose monohydrate carrier. In the formulation, the albuterol sulfate stabilises fluticasone propionate.
Bibliography:Application Number: EP20210765851